Life medicine最新文献_第2页

Liver regeneration: cytokine regulation targeting hepatocytes and beyond. 肝再生：针对肝细胞及其他细胞的细胞因子调控。

IF 6

Life medicine Pub Date : 2026-01-29 eCollection Date: 2026-02-01 DOI: 10.1093/lifemedi/lnag004

Ting Xiao, Zhangliu Jin, Jiangming Deng, Wen Meng

{"title":"Liver regeneration: cytokine regulation targeting hepatocytes and beyond.","authors":"Ting Xiao, Zhangliu Jin, Jiangming Deng, Wen Meng","doi":"10.1093/lifemedi/lnag004","DOIUrl":"10.1093/lifemedi/lnag004","url":null,"abstract":"The liver, the largest glandular organ in humans, exhibits a unique and robust regenerative capacity following injury. This regenerative response is orchestrated through a highly regulated network of cellular and molecular signals. Here, we review the cytokine-mediated regulation of liver regeneration, emphasizing autocrine, paracrine, as well as endocrine pathways. Hepatocyte proliferation is modulated not only by intrinsic signals but also by cytokines derived from non-parenchymal cells-including Kupffer cells, hepatic stellate cells, and liver sinusoidal endothelial cells-as well as by endocrine cues from the systemic circulation. From the perspective of metabolic reprogramming, these regulatory pathways illustrate how adaptive changes in glucose, lipid, and amino acid metabolism collectively sustain the cellular activities essential for liver regeneration. We further explore how metabolic adaptations contribute to regeneration, providing mechanistic insights and revealing potential therapeutic targets for liver diseases. Finally, we discuss emerging strategies that target cytokine networks and metabolic pathways to enhance liver regeneration, highlighting recent advances in translational applications.","PeriodicalId":74073,"journal":{"name":"Life medicine","volume":"5 1","pages":"lnag004"},"PeriodicalIF":6.0,"publicationDate":"2026-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12978310/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147446214","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Proteomic aging atlas identifies senoproteins as drivers of vascular and systemic senescence. 蛋白质组学衰老图谱确定衰老蛋白是血管和全身衰老的驱动因素。

IF 6

Life medicine Pub Date : 2026-01-29 eCollection Date: 2026-04-01 DOI: 10.1093/lifemedi/lnag003

Chongwei Bi, Mo Li

引用次数: 0

SIRT5 mitigates metabolic abnormality in murine models of metabolic dysfunction-associated steatotic liver disease. SIRT5减轻代谢功能障碍相关脂肪变性肝病小鼠模型中的代谢异常。

IF 6

Life medicine Pub Date : 2026-01-20 eCollection Date: 2026-04-01 DOI: 10.1093/lifemedi/lnag001

Min Xiao, Juncheng Zhao, Zixuan Dou, Xiangyu Chen, Sunyuntao Xu, Yu Zhang, Hongxuan Fan, Xudong Chen, Ping Zhang, Zhen Huang, Boda Zhou, Taotao Wei

引用次数: 0

Integration of a novel anti-PD-1 antibody with chimeric antigen receptor-T engineered to express interleukin-7 enhances targeting efficacy against lung cancer. 一种新的抗pd -1抗体与表达白细胞介素-7的嵌合抗原受体- t结合，增强了肺癌的靶向疗效。

IF 6

Life medicine Pub Date : 2025-12-23 eCollection Date: 2025-12-01 DOI: 10.1093/lifemedi/lnaf035

Chenxi Cheng, Lin Zhang, Jiani Cao, Xiaoyan Li, Ya Wen, Kun Liu, Tongbiao Zhao

引用次数: 0

Genetically engineered senescence-resistant human mesenchymal progenitor cells promote spinal cord injury repair. 基因工程抗衰老人间充质祖细胞促进脊髓损伤修复。

IF 6

Life medicine Pub Date : 2025-11-29 eCollection Date: 2026-02-01 DOI: 10.1093/lifemedi/lnaf038

Taixin Ning, Jinghui Lei, Xiaoyu Jiang, Shuhui Sun, Fangshuo Zheng, Qian Zhao, Shuai Ma, Weiqi Zhang, Jing Qu, Guang-Hui Liu, Si Wang

{"title":"Genetically engineered senescence-resistant human mesenchymal progenitor cells promote spinal cord injury repair.","authors":"Taixin Ning, Jinghui Lei, Xiaoyu Jiang, Shuhui Sun, Fangshuo Zheng, Qian Zhao, Shuai Ma, Weiqi Zhang, Jing Qu, Guang-Hui Liu, Si Wang","doi":"10.1093/lifemedi/lnaf038","DOIUrl":"10.1093/lifemedi/lnaf038","url":null,"abstract":"Spinal cord injury (SCI) is a devastating condition affecting the central nervous system, often leading to persistent neurological dysfunction. While mesenchymal progenitor cells (MPCs) hold considerable promise for treating various disorders, their application in SCI repair remains hampered by challenges such as poor efficacy and safety concerns. In this study, we developed genetically engineered human MPCs with enhanced resistance to senescence and stress-termed senescence- and stress-resistant cells (SRCs)-and systematically evaluated their therapeutic potential and mechanisms in SCI repair. Intramedullary implantation of SRCs improved functional recovery after SCI. Mechanistically, SRCs exerted therapeutic effects through a dual approach: by mitigating neuronal and axonal loss while stimulating endogenous neuroregeneration, and by suppressing neuroinflammation while modulating astrocyte distribution to restrict lesion expansion. Importantly, we identified exosomes derived from SRCs as key mediators of these reparative effects. Our findings provide comprehensive insights into the therapeutic role of engineered SRCs in SCI repair, delineating both direct cellular and exosome-mediated mechanisms, thus providing experimental support for future clinical translation.","PeriodicalId":74073,"journal":{"name":"Life medicine","volume":"5 1","pages":"lnaf038"},"PeriodicalIF":6.0,"publicationDate":"2025-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12909257/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146222332","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Senescent B cells regulate CD38 expression via FOXO1 in pneumonia resulting from PIK3CD (R437C) mutations. 在PIK3CD （R437C）突变引起的肺炎中，衰老B细胞通过fox01调节CD38的表达。

IF 6

Life medicine Pub Date : 2025-11-25 eCollection Date: 2025-10-01 DOI: 10.1093/lifemedi/lnaf030

Ju Liu, Yuxin Bai, Jianing Tang, Peiyao Jin, Yanmei Huang, Lu Yang, Ying Wang, Xiaochuan Wu, Chaohong Liu

{"title":"Senescent B cells regulate CD38 expression via FOXO1 in pneumonia resulting from PIK3CD (R437C) mutations.","authors":"Ju Liu, Yuxin Bai, Jianing Tang, Peiyao Jin, Yanmei Huang, Lu Yang, Ying Wang, Xiaochuan Wu, Chaohong Liu","doi":"10.1093/lifemedi/lnaf030","DOIUrl":"10.1093/lifemedi/lnaf030","url":null,"abstract":"Activated phosphoinositide 3-kinase delta syndrome (APDS) is a primary immunodeficiency characterized by hyperactivated lymphocytes and recurrent infections. This study presents a 2.5-year-old patient with a novel PIK3CD gene mutation (c.1309C>T; p. R437C) derived from his mother. We explored the immunological consequences of this mutation in both the patient and his mother, revealing defects in T cell differentiation, B cell maturation, and mitochondrial function. Notably, we found that the elevated CD38 expression on B cells is a key factor driving B cell senescence, mitochondrial dysfunction, and increased transitional B cell proportion, contributing to the observed immunodeficiency, such as diminished serum antibodies. Further investigations of the PI3K/AKT/mTOR pathway highlight a preferential activation of mTORC2 over mTORC1. We also demonstrate that the transcription factor FOXO1, a downstream molecule of PI3K/AKT signaling, regulates CD38 expression by binding to the promotor of the CD38 gene, linking this pathway to B cell dysfunction. This novel mutation expands the spectrum of PIK3CD mutations associated with APDS and provides new insights into the molecular mechanisms underlying B-cell senescence and other immune dysregulation. Moreover, targeting the AKT-FOXO1 axis could offer therapeutic potential to reverse B-cell dysfunction and improve immune responses in patients with PIK3CD mutations.","PeriodicalId":74073,"journal":{"name":"Life medicine","volume":"4 5","pages":"lnaf030"},"PeriodicalIF":6.0,"publicationDate":"2025-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12853000/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146109020","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Dual-modality theranostics probes: sintegrative strategies for precision management of oncologic malignancies. 双模治疗探针：肿瘤恶性肿瘤精准治疗的综合策略。

IF 6

Life medicine Pub Date : 2025-11-19 eCollection Date: 2026-02-01 DOI: 10.1093/lifemedi/lnaf037

Xilin Jing, Yutao Li, Yijing Zhang, Yuqi Wang, Xiaohua Jia, Xing Yang, Kezhong Chen

{"title":"Dual-modality theranostics probes: sintegrative strategies for precision management of oncologic malignancies.","authors":"Xilin Jing, Yutao Li, Yijing Zhang, Yuqi Wang, Xiaohua Jia, Xing Yang, Kezhong Chen","doi":"10.1093/lifemedi/lnaf037","DOIUrl":"10.1093/lifemedi/lnaf037","url":null,"abstract":"Cancer remains a formidable global public health challenge. Recent advancements in immunotherapy and targeted therapies have revolutionized diagnostic and therapeutic paradigms. Within this context, theranostics-an emerging field integrating molecular imaging with therapeutic interventions-has shown promise in achieving precision oncology. Central to theranostic platforms are dual-modality probes utilizing positron emission tomography, fluorescence, and magnetic resonance imaging technologies, which offer synergistic advantages such as complementary imaging modalities, intraoperative guidance, and real-time drug delivery monitoring. Despite growing research interest and early clinical trials, critical challenges persist in biosafety, metabolic stability, and imaging resolution. Structural optimization of probes and modality-specific selection based on cancer subtypes may address these limitations. This review systematically evaluates the design principles and clinical applications of dual-modality probes and proposes actionable strategies to enhance their translational potential.","PeriodicalId":74073,"journal":{"name":"Life medicine","volume":"5 1","pages":"lnaf037"},"PeriodicalIF":6.0,"publicationDate":"2025-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12812221/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146004792","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Integrating GLP-1 receptor agonists with anti-amyloid immunotherapy for Alzheimer's disease: a phased clinical roadmap. GLP-1受体激动剂联合抗淀粉样蛋白免疫疗法治疗阿尔茨海默病：分阶段临床路线图

IF 6

Life medicine Pub Date : 2025-11-14 eCollection Date: 2025-10-01 DOI: 10.1093/lifemedi/lnaf036

Junzhe Huang, Shengya Wang, Vincent C T Mok, Weihong Song, Ho Ko, Yun Zhang

引用次数: 0

Centenarians: a model of immune resilience against multimorbidity. 百岁老人：对抗多种疾病的免疫弹性模型。

IF 6

Life medicine Pub Date : 2025-10-13 eCollection Date: 2025-12-01 DOI: 10.1093/lifemedi/lnaf033

引用次数: 0

Explore sirtuin family: SIRT5 as a ticket for the entrance of the TBK1-RelA axis to skeletal muscle rejuvenation. 探索sirtuin家族：SIRT5作为TBK1-RelA轴进入骨骼肌年轻化的入场券。

IF 6